title: L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy.
abstract: It is well known that L-asparaginase (L-Ase) treatment may cause thrombotic events in patients with acute lymphoblastic leukemia (ALL). The mechanism of this effect is not well understood although a reduction in plasma antithrombin III (AT III) levels is observed. In our study, a group of patients treated with L-Ase received AT III concentrates as adjuvant treatment. This adjuvant treatment reduced the levels of plasma D-dimer and thrombin-antithrombin complex, which are considered as early markers of a hypercoagulability state. These preliminary data suggest that large randomized trials will have to be conducted to improve our understanding of the role of AT III concentrates in ALL therapy.
authors.affiliation: Istituto di Scienze Biomediche dell'Università di Milano, Italy.
authors.forename: E M
authors.initials: EM
authors.lastname: Pogliani
authors.forename: M
authors.initials: M
authors.lastname: Parma
authors.forename: I
authors.initials: I
authors.lastname: Baragetti
authors.forename: G
authors.initials: G
authors.lastname: Mostarda
authors.forename: F
authors.initials: F
authors.lastname: Rivolta
authors.forename: P
authors.initials: P
authors.lastname: Maffé
authors.forename: G
authors.initials: G
authors.lastname: Corneo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000990:Antithrombin III / Q000627:therapeutic use*; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D013927:Thrombosis / Q000097:blood* / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000990:Antithrombin III; D001215:Asparaginase